Payers and providers now expect RWE to complement trial efficacy by demonstrating effectiveness, utilization impact, and ROI ...
Formulary positioning and benefit design frequently determine utilization, as weak placement or reimbursement dynamics can ...
Integrated direct-to-patient models use AI-enabled eBenefits/eVerification plus real-time claims adjudication to surface ...
Supreme Court inaction leaves intact lower-court rulings rejecting takings and compelled-speech theories against “fair price” designations in Medicare price negotiation. Courts emphasized ...
BIOSECURE is catalyzing structural sourcing and manufacturing shifts, prompting reassessment of legacy partnerships and ...
Jeremy Richardson explains how direct-to-patient models increase drug pricing transparency and demonstrate value.
Makary’s tenure aligned FDA with MAHA priorities, including advocating placebo-controlled Covid-19 vaccine trials in ...
In today’s Pharma Pulse, FDA leadership changes with Makary’s resignation, Lilly shares new Zepbound and GLP-1 data, and new study data on prior authorization reform outlook. Welcome to Pharma Pulse, ...
Seventy-five executives across manufacturers and agencies backed a unified “system of work” to reduce multi-tool fragmentation across core commercial functions, reflecting a shift from tool ...
Will Shrank, MD, explains the main hurdles to specialty therapy access, and what will impact the market over the next few years. In the final part of Pharmaceutical Commerce’s conversation with Will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results